Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
06.08.2013 23:45:00

Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013

SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's Senior Vice President and Chief Commercial Officer Scott Byrd will present the company's corporate overview on Tuesday, August 13, 2013 at 12:45pm Eastern Time (9:45am Pacific Time) during the 2013 Wedbush PacGrow Life Sciences Management Access Conference at Le Parker Meridien Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section.  A replay of the webcast will be available approximately three hours after the live webcast concludes and will remain available for 30 days.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of www.cadencepharm.com under "Events & Presentations" by selecting "Corporate Overview."

Contacts:

William R. LaRue

SVP, CFO                                      

Cadence Pharmaceuticals, Inc.

858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.

Nachrichten zu Cadence Pharmaceuticals Inc Cash Settlement At USD 14.00 A Shmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Cadence Pharmaceuticals Inc Cash Settlement At USD 14.00 A Shmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!